富安娜(002327.SZ):購買的中信證券固收類理財產品本金1.065億元及投資收益逾期兑付
格隆匯8月23日丨富安娜(002327.SZ)公佈,公司於2021年3月19日購買1.2億元、期限12個月的“中信證券富安FOF定製1號單一資產管理計劃”(簡稱“富安1號”),到期日為2022年3月19日,該產品截至公吿日,公司共計收到產品本金1350萬元,剩餘產品本金1.065億元及投資收益到期未兑付。
公司多次通過函件、電話、視頻、現場會議等方式與中信證券溝通相關事項,就公司購買的“中信證券富安FOF定製1號單一資產管理計劃”目前情況及後續的兑付安排進行反覆溝通,公司敦促中信證券儘快處置富安1號底層資產,儘快做出兑付的實際行動及後續兑付安排。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.